Literature DB >> 7727855

[Drug resistance, oncogenes, and anti-oncogenes in epithelial tumors].

C Riva-Lavieille1.   

Abstract

Twenty four squamous cell carcinomas of the head and neck (HNSCC) of stage II to IV were evaluated for the expression of potential markers such as oncogenes and tumor suppressor genes in drug-resistance behavior. We have analysed the c-myc, c-jun, c-raf and N-ras and p53 expression in total RNA preparation from tumor biopsies obtained before treatment. The patients underwent chemotherapy including 5-fluorouracil and cisplatinum. No significant differences in c-raf and N-ras expression were found in responding or resistant patients. However, resistance to chemotherapy was associated with low expression of c-myc (P < 0.025) or high expression of c-jun (P < 0.001). In addition, p53 mRNA pre-therapeutic level was increased in unresponsive patients to chemotherapy (P < 0.05). Therefore, analysis of the expression of c-myc, c-jun oncogenes and p53 tumor suppressor gene in tumor cells before initiation of therapy may define a subset of patients with potentially better prognosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7727855

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  The role of oncogenes in drug resistance.

Authors:  D Yu
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.

Authors:  S L Deming; S J Nass; R B Dickson; B J Trock
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.